FSH and LH also control the onset of puberty in boys and girls. Therefore, administration of nafarelin blocks the puberty-promoting effects of FSH and LH, reducing the development of secondary sexual characteristics (such as pubic hair) and skeletal development in boys and girls with abnormally early puberty (central precocious puberty) due to problems in the brain that result in high levels of FSH and LH. The FDA approved nafarelin in February 1991.
PRESCRIBED FOR: Nafarelin is prescribed for the management of endometriosis, to relieve pain and shrink endometrial implants. It also is used for managing central precocious puberty.
SIDE EFFECTS: Side effects of nafarelin are mostly related to the low estrogen state. Common side effects include:
Other important side effects include:
These side effects should disappear after stopping the medication.
The low estrogen state and the temporary menopause induced by nafarelin can cause a small amount of bone thinning, which may only partially recover after stopping treatment. Patients should discuss this possibility with their doctors and alert their doctors to conditions that they may have that could increase the risk of bone thinning. These conditions include chronic tobacco use, excessive use of alcohol, family history of osteoporosis, and taking other medications that can cause bone thinning (such as anticonvulsants or corticosteroids).
Quick GuideEndometriosis Symptoms, Stages, Treatment
Report Problems to the Food and Drug Administration
Need help identifying pills and medications?
Use the pill identifier tool on RxList.